Acute Coronary Syndrome: STEMI and NSTEMI Management Updates for 2026

Complete Revascularization in STEMI: COMPLETE and Beyond

Acute coronary syndrome management evolves with each major trial, and the past several years have produced data that directly change how cardiologists and interventionalists approach revascularization strategy, antiplatelet therapy, and the timing of invasive evaluation. For the cardiologist managing STEMI in the catheterization lab, the interventionalist deciding whether to address non-culprit lesions, the hospitalist managing NSTEMI on the floor, and the primary care physician optimizing secondary prevention after discharge, the landscape has shifted in clinically meaningful ways. This review covers the trials that matter most for the decisions you make in daily practice.

The COMPLETE trial (4,041 STEMI patients with multivessel disease) demonstrated that staged complete revascularization of non-culprit lesions reduced the composite of cardiovascular death or MI by 26% (HR 0.74, 95% CI 0.60-0.91)[1] compared to culprit-only PCI. The benefit was driven primarily by a reduction in MI (HR 0.68). Patients with concomitant peripheral artery disease require additional consideration[2]. The FIRE trial extended this evidence to patients over 75 years old, confirming benefit in the elderly with a 27% reduction in all-cause death, MI, or stroke at 1 year[3].

The MULTISTARS AMI trial addressed timing, demonstrating that immediate complete revascularization during the index procedure was non-inferior to staged complete revascularization[4], with a trend toward lower all-cause death or MI at 1 year (HR 0.77, 95% CI 0.54-1.11). This supports operator flexibility in managing non-culprit lesions during the initial catheterization when anatomy is favorable.

Antiplatelet Therapy: De-Escalation Strategies

The TWILIGHT trial established that ticagrelor monotherapy after 3 months of DAPT reduced BARC 2-5 bleeding by 44% (HR 0.56, p<0.001) without increasing ischemic events[5]. The HOST-EXAM trial showed clopidogrel monotherapy was superior to aspirin monotherapy after 6-18 months of DAPT post-PCI, reducing a composite of cardiovascular events and bleeding by 27%[6]. The STOPDAPT-3 trial introduced an aspirin-free strategy with prasugrel monotherapy from the time of PCI[7], though results were mixed on ischemic outcomes.

De-Escalation in Practice: Who and When

The de-escalation antiplatelet strategy addresses a genuine clinical tension: the highest risk of stent thrombosis is in the first weeks after PCI, while the cumulative bleeding risk from dual antiplatelet therapy increases the longer it continues. Shortening the DAPT duration from 12 months to 1-3 months followed by P2Y12 inhibitor monotherapy reduces bleeding without a measurable ischemic cost in most patients. The practical question is patient selection. High-bleeding-risk patients (elderly, prior bleeding, concurrent anticoagulation, low body weight) benefit most from early de-escalation. Patients with complex PCI (left main stenting, bifurcation lesions, long total stent length) may warrant longer DAPT. The conversation with the patient should explicitly address this tradeoff: "We are reducing one of your blood thinners because the risk of bleeding now outweighs the small residual risk of stent clotting."

NSTEMI: Early Invasive vs Conservative Strategy

The ISCHEMIA trial established that an initial invasive strategy did not reduce death or MI compared to optimal medical therapy in stable ischemic heart disease[8]. However, the ESC 2023 guidelines maintain that very-high-risk NSTEMI patients (hemodynamic instability, ongoing chest pain, life-threatening arrhythmias including atrial fibrillation, acute heart failure) should undergo immediate angiography within 2 hours. High-risk patients (GRACE score >140, troponin rise/fall, dynamic ST changes) should undergo early angiography within 24 hours.